by SpiSafConf | Aug 12, 2022 | Bipolar Disorder, Chronic Pain, Kambo, LSD, MDMA Sassafras Molly, Microdosing, NN-Dimethyltryptamine, OCD, Psilocybin Magic Mushroom, Psychedelic Medicine
COULD AN OVERACTIVE IMMUNE SYSTEM make you depressed? In the late 1990s, psychiatrist Andrew Miller and his colleagues began to notice that patients with cancer, cardiovascular disease, obesity and Crohn’s disease—all conditions that cause higher than normal levels of...
by SpiSafConf | Aug 11, 2022 | Psychedelic Research
After two blinded experimental sessions, the active group had significantly greater reductions in CAPS-IV total scores from baseline than the control group [MMRM estimated mean difference (SE) between groups − 22.0 (5.17), P < 0.001]. The between-group Cohen’s d...
by SpiSafConf | Aug 11, 2022 | Psychedelic Research
In the intent-to-treat set, the active groups had the largest reduction in Clinician-Administered PTSD Scale total scores at the primary endpoint, with mean (standard deviation) changes of −26.3 (29.5) for 125 mg, −24.4 (24.2) for 100 mg, and −11.5 (21.2) for 40 mg,...
by SpiSafConf | Aug 11, 2022 | Psychedelic Research
Analyses of daily ratings revealed a general increase in reported psychological functioning across all measures on dosing days but limited evidence of residual effects on following days. Analyses of pre and post study measures revealed reductions in reported levels of...
by SpiSafConf | Aug 11, 2022 | Psychedelic Research
Results indicated that psilocybin enhanced divergent thinking and emotional empathy the morning after use. Enhancements in convergent thinking, valence-specific emotional empathy, and well-being persisted seven days after use. Sub-acute changes in empathy correlated...
